|
|
|
Analysts'
Recommendation: | Buy | | 30 Days Ago: | Buy |
| | Analysts' Target: | $38 | | Analysts' Targets | | Roth Capital Partners | $52 | | Buy | Thursday, April 24, 2008
| | JMP Securities LLC | $23 | | Mkt Underperform | | Friday, January 25, 2008 | Celera Corporation delivers personalized disease management products and services in the United States. It offers clinical laboratory testing and disease management services comprising LDL-S3GGE, HDL-S10GGE, and Apolipoprotein E Genotypes tests to enable healthcare providers optimize cardiovascular disease treatment regimens for patients. The company also offers molecular diagnostic products that facilitate disease detection, prediction of disease predisposition, monitoring of disease progression and disease severity, and determination of patient responsiveness to treatments. Celera Corporation offers ViroSeq HIV-1 Genotyping System that enables healthcare providers in monitoring and treating HIV-1 infection and includes reagents for identifying key mutations of the HIV-1 genome designed for use on an automated DNA sequencing instrument; Cystic Fibrosis products for detecting mutations in the cystic fibrosis transmembrane conductance regulator gene, which cause cystic fibrosis; hepatitis C virus analyte specific reagents (ASRs) to measure viral load that refers to the quantity of the virus found in a tissue sample; ASRs for detecting mutations in the FMR-1 gene, which cause Fragile X Syndrome; and ASRs for detecting mutations in genes known to be involved in deep vein thrombosis. In addition, it manufactures ASRs and capillary electrophoresis marked products for defining high resolution human leukocyte antigens, as well as provides contract manufacturing and technology development services for the development and manufacture of reagents for use by the clinical laboratories in the clinical testing services. It has a strategic alliance with Abbott Laboratories to develop and commercialize molecular diagnostic products for disease detection, prediction of disease predisposition, disease progression monitoring, and therapy selection. The company was founded in 1937 and is based in Alameda, California.
|
CRA:
This call was made
on 07/13/08
@ $12.68
| Rating: |
$12.68 (07/13/08)
|
| Closed: |
08/05/2009
@ $6.0599
(-52.21%
in
387 days)
|
| Target: |
$23.00
(+81.39%)
in > one year
|
| Allocation: |
0.0% of portfolio
|
|
